Clarion Medical Technologies Inc. to Distribute Health Canada Approved DWP-450(prabotulinumtoxinA) in Canada
CAMBRIDGE, ON, Aug. 22, 2018 /CNW/ - Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic equipment and consumables, is pleased to be the Canadian partner to Evolus, Inc.'s Health Canada approved DWP-450 (prabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows seen at maximum frown) in adult patients under 65 years of age.
"The DWP-450 neurotoxin represents an exciting addition to Clarion's comprehensive aesthetic portfolio of equipment, dermal fillers, skincare and breast implants" commented Samson Ling, President and Chief Executive Officer of Clarion Medical Technologies. "We pride ourselves on offering quality aesthetic solutions to our customers and are confident that DWP-450 will provide a valuable option to physicians and consumers in 2019."
About Clarion Medical Technologies Inc.
Clarion Medical Technologies is a leading Canadian provider of medical and aesthetic equipment and consumables to hospitals, aesthetic clinics and private medical practices. The company specializes in aesthetic, otolaryngology, gynecology, urology and vision applications. Clarion Medical's strength is on harnessing the power of innovative technologies, the talents of our people and the expertise of our partners to deliver innovative solutions that improve healthcare. Products and services offered include: laser technologies, diagnostic equipment, skincare, dermal fillers, intra-ocular lenses, laser fibers, clinical education, laser safety, technical support, and regulatory and marketing services.
SOURCE Clarion Medical Technologies Inc.